ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AstraZeneca sells US rights to RSV therapy Synagis to Sobi for $1.5 billion upfront
November 13, 2018AstraZeneca announced Tuesday an agreement to sell US rights to Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for a total upfront consideration of $1.5 billion, including $1 billion in cash. Under the deal for the respiratory syncytial virus (R
Pharma Sources Insight January 2025
